Open-Label, Part-Randomized Study Designed to Evaluate the PK Profile of Tenofovir Exalidex (TXL) Following Single Dose of Oral Formulations in Comparison to a Reference IR TXL Tablet in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Aug 2018
At a glance
- Drugs Tenofovir exalidex (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors ContraVir Pharmaceuticals
- 31 Jul 2018 Status changed from recruiting to completed.
- 28 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Jun 2018.
- 28 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2018.